palbociclib
pfizer
['pallas', 'palbo', 'palbociclib']
#asco23
pallas trial: a preplanned analysis of the stage iia cohort mfu: 50 months adjuvant palbociclib does not contribute to idfs and other secondary endpoints presented by dr. angela demichele 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm